WOW! POT CURES LIVER CANCER I KNEW IT!!!!
Can-Fite cannabis compound inhibits liver cancer growth
Apr. 05, 2021 7:43 AM ETCan-Fite BioPharma Ltd. (CANF)
Can-Fite cannabis compound inhibits liver cancer growth
Apr. 05, 2021 7:43 AM ETCan-Fite BioPharma Ltd. (CANF)
- Can-Fite BioPharma(NYSEMKT:CANF)hascompletedpre-clinical studies demonstrating that a CBD rich T3/C15 cannabis fraction induces inhibition of liver cancercell growth.
- T3/C15 cannabis fraction inhibited the growth of liver HEP-3b hepatocellular carcinoma cells via the A3 adenosine receptor (A3AR) by inhibiting Wnt- and NF-kappa B-related regulatory pathways, known to be highly active in controlling the growth of liver cancer cells.
- An A3AR antagonist, MRS1523 reversed this effect demonstrating that the inhibitory effect is mediated via Can-Fite’s target, A3AR.
- Can-Fite drug candidate Namodenoson is expected to enter a Phase III study in Q4 2021.
- The Company has filed patent applications protecting its discovery of cannabinoid-based therapies where the A3AR target is overexpressed including liver cancer.
- According to Adroit Market Research, the medical cannabis market is projected to grow at a CAGR of 29% to $56.7B by 2026. DelveInsight estimates the HCC drug market will reach $3.8 B in 2027 in the G8 countries.
- CANF shares up 5.7% premarket trading at $2.59.<----
